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Abstract: Pinnatoxins (PnTXs) A-H constitute an emerging family belonging to the cyclic imine
group of phycotoxins. Interest has been focused on these fast-acting and highly-potent toxins because
they are widely found in contaminated shellfish. Despite their highly complex molecular structure,
PnTXs have been chemically synthetized and demonstrated to act on various nicotinic acetylcholine
receptor (nAChR) subtypes. In the present work, PnTX-A, PnTX-G and analogue, obtained by
chemical synthesis with a high degree of purity (>98%), have been studied in vivo and in vitro on
adult mouse and isolated nerve-muscle preparations expressing the mature muscle-type (α1)2β1δε
nAChR. The results show that PnTX-A and G acted on the neuromuscular system of anesthetized
mice and blocked the compound muscle action potential (CMAP) in a dose- and time-dependent
manner, using a minimally invasive electrophysiological method. The CMAP block produced by both
toxins in vivo was reversible within 6–8 h. PnTX-A and G, applied to isolated extensor digitorum
longus nerve-muscle preparations, blocked reversibly isometric twitches evoked by nerve stimulation.
The action of PnTX-A was reversed by 3,4-diaminopyridine. Both toxins exerted no direct action on
muscle fibers, as revealed by direct muscle stimulation. PnTX-A and G blocked synaptic transmission
at mouse neuromuscular junctions and PnTX-A amino ketone analogue (containing an open form of
the imine ring) had no effect on neuromuscular transmission. These results indicate the importance
of the cyclic imine for interacting with the adult mammalian muscle-type nAChR. Modeling and
docking studies revealed molecular determinants responsible for the interaction of PnTXs with the
muscle-type nAChR.
Keywords: pinnatoxins; marine phycotoxins; mouse neuromuscular system; compound muscle
action potential; synaptic potentials; emerging toxins; cyclic imines
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1. Introduction
Pinnatoxins (PnTXs) A–D were originally identified in the digestive glands of the bivalve mollusks
Pinna attenuata and Pinna muricata following food poisoning outbreaks that were linked to these
shellfish in China and Japan [1–4]. However, it is still unclear whether PnTXs were the cause of
these poisoning events. Later, three new PnTX-A analogues, the PnTX-E, F, and G, were isolated and
structurally characterized from extracts of Pacific oysters (Crassostrea gigas) and razorfish (Pinna bicolor)
from South Australia [5,6].
Analysis of surface sediments in New Zealand and South Australia, where shellfish were reported
positive for PnTXs, led to the discovery of a peridinoid dinoflagellate producing PnTX-E and F in
New Zealand, PnTX-E, F, and G in South Australia [7–9] and PnTX-G in Japan [10]. Morphological
and phylogenetic similarities were observed between these dinoflagellates and a new dinoflagellate
named Vulcanodinium rugosum discovered in water samples of Mediterranean lagoons in the French
coast [11]. Contamination of mussels and clams by PnTXs, and the link to the V. rugosum dinoflagellate
was first reported in France in 2011 [12], but retro-analysis of contaminated shellfish samples revealed
high levels of PnTX-G since 2006 [13]. Likewise, PnTXs have been found in other European waters
and seafood since 2010 [14–18], and in Canada as well [19]. There is also evidence that the harmful
V. rugosum dinoflagellate can be transported in ballast tanks of shipping vessels [20], which is of global
concern. Also, new strains of the V. rugosum dinoflagellate, isolated from the South China Sea [21] and
the Arabian Gulf [22], were reported to produce only PnTX-H and portimine [21,23], as determined by
liquid chromatography-tandem mass spectrometry (LC-MS/MS).
PnTXs belong to a heterogeneous and growing group of macrocyclic compounds called “cyclic
imines toxins” that include the prorocentrolides, spiro-prorocentrimine, gymnodimines, spirolides,
pteriatoxins, and portimines ([24–26] for reviews, and [27,28] for recently described cyclic imine toxins).
Up until now, eight PnTXs (A–H) have been reported. Their chemical structure contains a common
scaffold characterized by a dimethyl substituted 7-membered cyclic imine as part of a spiroimine
ring system, a 6,5,6-spiroketal ring system, and a bridged ketal which is typical of this family of
toxins [24–26], as exemplified for PnTX-A and G in Figure 1. It has been proposed that PnTX-F and
G are the precursors of all PnTXs, as well as of the structurally related pteriatoxins, via metabolic
and hydrolytic transformations in shellfish [6]. Interestingly, in contrast to other cyclic imine toxins,
PnTXs exhibit an outstanding chemical stability at acid pH (pH 1.5 and pH 4.0) [6,29].
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In mouse bioassays, PnTx-E, F, and G were shown to produce rapid lethality by respiratory
depression upon intraperitoneal administration, with both neurological symptoms and skeletal muscle
flaccid paralysis [6,23,30]. Among the cyclic imine phycotoxins purified, PnTX-E, F, and G were the
ones that exhibited the highest acute oral mouse toxic ty [30].
PnTXs, like other cyclic imine toxins, are known to be potent antagonists of bothTorpedomuscle-type
(α12β1γδ) and neuronalα7, α4β2 andα3β2 nicotinic acetylcholine receptors (nAChRs) [31–33]. Studies
on isolated rat phrenic-hemidiaphragm preparations showed that crude extract containing a mixture
of PnTX-E and PnTX-F, as well as purified PnTX-F [34] and purified PnTX-E, PnTX-F, and PnTX-G [35]
produced concentration-dependent decreases in nerve-evoked muscle twitches with a rank order of
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potency of PnTX-F > PnTX-G > PnTX-E, incomplete washout profiles for PnTX-F and PnTX-G, and the
inability to be reversed by the anticholinesterase inhibitor neostigmine [34,35].
To the best of our knowledge, neither PnTX-A nor PnTX-G, obtained by chemical synthesis and
having an established degree of purity (>98%), have been studied in vivo and in vitro on adult mouse
and isolated nerve-muscle preparations expressing the mature muscle α12β1δε nAChR. Therefore,
aims of the current study were (i) to study the local action of synthetic PnTX-A and G on the
neuromuscular system of anesthetized mice in vivo, using a minimally invasive electrophysiological
method, (ii) to study in vitro the actions of PnTX-A and G, as well as PnTX-A amino ketone
derivative (PnTX-AK, containing an open form of the imine ring), on isometric twitch tension
and on cholinergic transmission at single neuromuscular junctions, (iii) to determine the eventual
efficacy of 3,4-diaminopyridine for reversing the neuromuscular blockade produced by PnTX-A and G,
and (iv) to model the molecular interactions between PnTX-A and G and the α12β1δε nAChR.
2. Results
2.1. Effects of PnTX-A and G on the Excitability Properties of Mouse Neuromuscular System In Vivo
The effects of intramuscular injections of PnTX-A and G were studied on the multimodal excitability
properties of the mouse neuromuscular system in vivo (Figure 2).
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Figure 2. Effects of lo al inje tio s of PnTX-A and G on the multimodal excita t roperties of mouse
neuromuscular syste in vivo. (a) Traces of CMAP recorded from the tail muscle following increasing
intensities of caudal motor nerve stimulation (scheme), before (control) and after injection of PnTX-A
(5.44 nmol/kg of mouse, upper traces) or PnTX-G (3.20 nmol/kg of mouse, lower traces). (b) On-line
recordings of the effects of PnTX-A (5.44 nmol/kg of mouse), PnTX-G (3.20 nmol/kg of mouse) and/or
methanol (1%) injections on the CMAP maximal amplitude registered continuously over time. Values
are expressed relatively to those before injections. The arrow indicates the time of injections.
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On-line recordings were initiated approximately 10 min before a given injection of PBS containing
methanol (0.1–1%) and various doses of either PnTX-A (from 0.54 to 5.44 nmol/kg of mouse) or PnTX-G
(1.60 and 3.20 nmol/kg of mouse), to observe the alterations occurring on some selected excitability
parameters, such as the CMAP amplitude and excitability threshold, registered continuously over time.
The major effect of the two toxins was a decrease of CMAP amplitude, as exemplified in Figure 2a,b for
5.44 nmol of PnTX-A per kg of mouse and 3.20 nmol of PnTX-G per kg of mouse. This effect occurred
at various times, depending on the dose of toxin injected [PnTX-A: from 43.3 ± 0.2 min (n = 3 mice) for
0.54 nmol/kg of mouse to 26.1 ± 7.7 min (n = 4 mice) for 5.44 nmol/kg of mouse, and PnTX-G: from
24.4 ± 9.7 min (n = 4 mice) for 1.60 nmol/kg of mouse to 15.5 ± 7.0 min (n = 4 mice) for 3.20 nmol/kg of
mouse]. The toxin-induced decrease of CMAP amplitude was completely reversed within 6-8 h after
PnTX-A (5.44 nmol/kg of mouse) or PnTX-G (3.20 nmol/kg of mouse) injection, leading to a 93.7 ± 8.0%
(n = 8 mice) recovery compared to control conditions, i.e., CMAP amplitude before injection (Figure 2a).
Finally, the CMAP amplitude remained stable before toxin injections, or before and after injection
(5 µL) of PBS added only with 1% methanol (Figure 2b). Under these latter conditions, the CMAP
maximal amplitude was not significantly affected (P = 0.332), i.e., 95.0 ± 5.6% within 57.7 ± 13.3 min
(n = 3 mice), compared to control conditions. This indicates that injections of the vehicle associated to
the highest doses of toxin studied had no significant effect on the CMAP amplitude.
The dose-response curves of PnTX-A and G effects on the CMAP maximal amplitude were
established and analyzed using individual values instead of mean values, for a better comparison of the
efficacy between the two toxins. Results reveal that the doses necessary to inhibit 50% of the response
(ID50) was 3.1 ± 0.2 (n = 18 mice) and 2.8 ± 0.1 (n = 8 mice) nmol/kg of mouse, respectively (Figure 3).
These two ID50 values were not significantly different (P = 0.123). The comparison of PnTX-A and
G ID50 values to those of some other cyclic imine toxins previously studied, i.e., gymnodimine-A
(GYM-A) [36], 13-desmethyl spirolide C (13-SPX-C) [36] and 20-methyl spirolide G (20-meSPX-G) [37],
shows that PnTX-A and G were as potent as GYM-A, but at least 300-fold less efficient than 13-SPX-C
and 20-meSPX-G, to inhibit the CMAP maximal amplitude (Table 1).
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and 1.6 ± 0.2 (n = 18 mice) for PnTX-A, and 2.8 ± 0.1 nmol/kg of mouse and 2.7 ± 0.3 (n = 8 mice)
for PnTX-G.
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The five different excitability tests (stimulus-response, strength-duration and current-threshold
relationships, as well as threshold electrotonus and recovery cycle), performed together before and
approximately 45 min after injections of PBS containing methanol (1%) and either PnTX-A (5.44 nmol/kg
of mouse) or PnTX-G (3.20 nmol/kg of mouse) did not reveal further effects of the two toxins since no
apparent modification of excitability waveforms was detected (data not shown). This was confirmed
by analyzing the parameters determined from excitability tests, as exemplified in Table 2 for PnTX-A,
with the exception of a significant lower “TEd (undershoot)” after PnTX-A-injection. Although this
result may be due to alterations in slow voltage-gated K+ channels, it was not confirmed by analyzing
the other parameters (such as “TEd (40–60 ms)”, “TEd (90–100 ms)” and “TEd (accommodation)”)
related to this type of ion channel.
Table 1. ID50 values (in nmol/kg of mouse) of some cyclic imine toxins, determined from CMAP
maximal amplitude recorded from mouse tail muscle in vivo.
ID50 PnTX-A PnTX-G GYM-A 13-SPX-C 20-meSPX-G
Mean 3.080 2.830 3.474 0.009 0.002
S.D. 0.203 0.090 0.166 0.001 0.000
n (mice) 18 8 15 19 26
Reference Present study Present study [36] [36] [37]
Table 2. Excitability parameters (means ± S.D.) from tail muscle recordings of mice in vivo, before
(control, n = 15 mice) and approximately 45 min after injection of PBS containing methanol (1%) and
PnTX-A (5.44 nmol/kg of mouse, n = 8 mice).
Test 1 Excitability Parameter 2 Control PnTX-A P
T1
Peak response (mV) 3.299 ± 1.140 1.847 ± 1.370 0.050 *
Latency (ms) 3.359 ± 0.065 3.349 ± 0.106 0.893
Stimulus (mA) for 50% max response 0.481 ± 1.060 0.479 ± 1.130 0.927
Stimulus-response slope 3.004 ± 1.180 2.650 ± 1.310 0.743
T2
Resting slope 0.638 ± 0.077 0.916 ± 0.257 0.182
Minimum slope 0.230 ± 0.013 0.218 ± 0.022 0.703
Hyperpolarizing slope 0.536 ± 0.071 0.490 ± 0.074 0.757
T3
Strength-duration time constant (ms) 0.377 ± 0.035 0.316 ± 0.036 0.274
Rheobase (mA) 0.333 ± 1.070 0.327 ± 1.130 0.861
T4
TEd (10–20 ms) 47.680 ± 2.570 45.250 ± 4.930 0.700
TEd (peak) 48.640 ± 2.320 45.240 ± 4.110 0.555
TEd (40–60 ms) 39.440 ± 3.000 38.080 ± 1.980 0.826
TEd (90–100 ms) 36.000 ± 3.010 35.230 ± 1.810 0.878
TEd (accommodation) 12.590 ± 1.230 10.170 ± 2.890 0.441
TEd (undershoot) −11.820 ± 1.120 −5.188 ± 0.512 0.019 *
TEh (10–20 ms) −97.600 ± 4.780 −86.230 ± 2.660 0.318
TEh (20–40 ms) −132.000 ± 8.430 −123.900 ± 7.160 0.686
TEh (90–100 ms) −159.20 ± 12.60 −150.300 ± 4.910 0.753
TEh (overshoot) 13.350 ± 1.460 7.238 ± 1.450 0.079
T5
Relative refractory period (ms) 2.349 ± 1.090 2.532 ± 1.100 0.632
Superexcitability (%) −7.596 ± 1.490 −9.049 ± 1.970 0.600
Subexcitability (%) 3.844 ± 0.708 3.316 ± 1.160 0.697
1 T1 = Stimulus-response relationship, T2 = Current-threshold relationship (informed on accommodation capacity
to depolarizing and hyperpolarizing currents), T3 = Strength-duration relationship (informed on nodal membrane
potential), T4 = Threshold electrotonus and T5 = Recovery cycle. 2 TEd = Threshold electrotonus from depolarizing
currents and TEh = Threshold electrotonus from hyperpolarizing currents. *: Significant difference compared
to control.
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2.2. Effects of PnTX-A and G on Isometric Twitch Tension In Vitro
PnTX-A (2.8–84 nM) and PnTX-G (2.5–40 nM) when applied to isolated peroneal nerve-extensor
digitorum longus (EDL) muscle preparations produced a concentration- and time-dependent reduction
of the peak force amplitude of muscle twitches evoked by nerve stimulation at 0.03 Hz. Representative
twitch-tension recordings are shown in Figure 4a. The onset of the neuromuscular block was fast
with the higher concentration of PnTX-A used (84 nM), reaching 50% block in 5.1 ± 0.85 min (n = 3),
and 100% block in 16.5 ± 1.5 min (n = 3). The time course of PnTX-A and PnTX-G actions on the relative
isometric twitch amplitude are shown in Figure 4a,b. Although PnTX-G was more active than PnTX-A
on nerve-evoked twitch responses, onset of the block was about two-times slower with PnTX-G as
compared to PnTX-A (Figure 4b,c). Further experiments are needed for an understanding of the
slower onset kinetics but higher potency of PnTX-G compared to PnTX-A. Complete and rapid reversal
of PnTX-A induced neuromuscular block was obtained by addition of 100 µM 3,4-diaminopyridine
(3,4-DAP) to the medium (Figure 4a,b).
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Figure 4. PnTX-A blockade of nerve- is tric t itch tension without modification of directly
elicited twitch and tetanus tension on isolate o se scles. (a) (a1) Single twitch tension
recording under control conditions, (a2) arked reduction in twitch amplitude during the action of
PnTX-A (54 nM), (a3) Reversal of the blockade produced by PnTX-A by 3,4-DAP (100 µM). (a4,a5)
Twitch and tetanus responses evoked by direct muscle stimulation at 0.03 and 80 HZ, respectively
in an EDL muscle in which nerve-evoked contractions were completely blocked by 56 nM PnTX-A.
(b,c) Time course and concentration dependence of PnTX-A and PnTX G effects on nerve-evoked twitch
responses, and the reversal by wash-out and 3,4-DAP (100 µM). After an equilibration period of 20
min PnTXs were applied at time 0. In (b) the wash-out of PnTX-A (84 nM), and the fast reversal of
PnTX-A action by 3,4-DAP are shown. Note the slower onset kinetics of PnTX-G (c) as compared to
PnTX-A (b) on nerve-evoked muscle contraction. Each value is expressed relatively to that obtained
before addition of PnTXs.
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The relative potencies of PnTX-A and G were evaluated by concentration-response curves.
Calculation of the mean inhibitory concentration producing 50% reduction (IC50) of the isometric
twitch response was of 27.7 nM for PnTX-A and 11.3 nM for PnTX-G (Figure 5a,b). The action of PnTX-A
was reversible by washing out the toxin from the bathing medium within 120 min. Interestingly,
in EDL muscles in which full block of nerve-evoked contraction was produced by either PnTX-A
or PnTX-G, direct electrical muscle stimulation could still evoke twitch and tetanic contractions in
response to single and tetanic direct muscle stimulation, respectively. A representative example is
shown in Figure 4 (a4,a5). These results indicate that both PnTX-A and G exerted no direct action on
the contractile machinery of muscle fibers, but acted on neuromuscular transmission, as previously
shown for other cyclic imine toxins [37–39].
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Figure 5. Concentration-response curves for PnTX-A (a) and PnTX-G (b) actions on the isometric twitch
responses evoked by nerve stimulation (closed circles) or by direct muscle stimulation (open circles).
Data points represent the mean ± S.D. of twitch response, after 60 min toxin exposure, relative to the
respective controls of 3–6 EDL nerve-muscle preparations. The curves were calculated from typical
sigmoid non-linear regression through data points (r2 = 0.989 and 0.922 for PnTX-A and G, respectively).
The dose required to block 50% of the twitch amplitude (IC50) and nH were, respectively, 27.7 nM and
2.4 for PnTX-A, and 11.3 and 2.7 for PnTX-G.
2.3. Effects of PnTX-A and G on Neuromuscular Transmission In Vitro
To evaluate the action of PnTXs on synaptic transmission, intracellular recordings at single
neuromuscular junctions were performed from isolated EDL or FDB muscles. Experiments were
first done in standard Krebs-Ringer solution containing physiological Ca2+ concentration (2 mM).
Intracellular recordings at junctional regions of muscle fibers revealed that single nerve stimulation
always triggered an action potential that sometimes dislodged the microelectrode due to the contraction
of muscle fibers (Figure 6a). Muscle action potential triggered by nerve stimulation had overshoots
of 21.3 ± 1.61 mV when recorded at mean resting membrane potential of −69.3 ±.1.06 mV (n = 16,
4 different EDL muscles). As shown in Figure 6b, addition of PnTX-A (84 n ) to the standard
physiological medium completely abolished, within 30 min, the generation of muscle action potentials
u n erve stimulation. In addition, by recordings in junctional areas, these experiments revealed the
pr senc of end-plate potentials (EPPs) of 3–5 mV amplitude that were unable to reach the threshold for
action potential generation in muscle fibers. Similarly, when using a “floating” microelectrode, it was
possible to record muscle action potentials in FDB muscles without movement-bias due to contraction
(Figure 6c). Action potentials recorded under this condition were not significantly different from those
successfully recorded with conventional microelectrodes (P < 0.05, n = 9).
Additional experiments were performed using µ-conotoxin GIIIB (1.0–1.6 µM) which blocks
specifically and irreversibly voltage-gated skeletal muscle Na+ channels [40]. Under this condition,
full-sized EPPs could be evoked by nerve stimulation without contraction, as shown in a representative
Mar. Drugs 2019, 17, 306 8 of 17
recording in Figure 6d. Further addition of PnTX-A markedly reduced the amplitude of the full-sized
EPPs (Figure 6e).
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potential recorded in a junction of the E L uscle upon nerve sti ulation. (b) EPP recorded 30 in
after the addition of PnTX-A (84 nM) to the standard Krebs-Ringer solution. (c) Muscle action potential
recorded with a “floating” microelectrode in the FDB muscle upon nerve stimulation. (d) Full-sized
EPP recorded after treatment with µ-conotoxin GIIIB (1.6 µM) in a junction of the FDB muscle. (e) EPP
of reduced amplitude recorded after the action of PnTX-A. Recordings in (a) and (b) were obtained
at a resting membrane potential of −70 mV, and those in (c) and (d,e) were obtained at −68 and
−71 mV, respectively.
Both PnTX-A and G significantly blocked (P < 0.05) by more than 80% full-sized EPP amplitudes,
recorded in muscles treated with µ-conotoxin GIIIB as shown in Figure 7. These results indicate
that these toxins block neuromuscular transmission by reducing the amplitude of EPPs. It is worth
noting that no significant change on the resting membrane potential of muscle fibers was detected
in the presence of PnTX-A and G in the range of concentrations studied (P > 0.05; n = 12 and n = 9,
respectively).
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Further experiments were performed to determine whether miniature end-plate potentials
(mEPPs), which result from the release of a single quantum of ACh, are modified in amplitude and
frequency by the PnTXs. Under control conditions, the mean amplitude of mEPPs recorded in standard
Krebs-Ringer solution in unstimulated junctions from the EDL muscles was 0.92 ± 0.03 mV (n = 6,
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from 6 different muscles), addition of 5 nM PnTX-A or G to the medium induced a significant reduction
and complete block of mEPP amplitude within 25 min with both toxins (n = 3, from 3 different muscles
in each condition). The block of mEPP amplitude was fully reversible upon washing (within 30 min) of
the nerve-muscle preparations with a toxin-free medium. Estimations of the frequency of mEPPs when
mEPP were blocked by about 50%, but still easily recognized from the basal electric noise, revealed
that the frequency was not significantly modified (Figure 8b).
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Figure 8. PnTX-A and PnTX-G block of mEPP amplitude without affecting mEPP frequency. (a) Control
mEPP amplitude (white column), after 10 min and 20 min of 5 nM PnTX-A action (blue columns),
and 5 nM PnTX-G action (brown column). (b) Frequency of mEPP recorded under control conditions
(white column) and after 10 min of 5 nM PnTX-A action (blue column) when mEPPs of reduced
amplitude were still present. Note, under this condition, the lack of action of PnTX-A on mEPP
frequency. (c) Examples of mEPPs recorded under control conditions and during the action of 5 nM
PnTX-G (brown traces). *: denotes significant differences compared to controls (P < 0.05).
Overall, our results show that synaptic transmission is strongly impaired by both PnTX-A and G,
and suggest that both phycotoxins block, in a reversible manner, the interaction of ACh quanta with
endplate nAChR.
To determine if PnTXs modified the sensitivity of nAChR to extracellularly applied ACh,
an intracellular recording microelectrode was impaled, as close as possible to the endplate area,
so that mEPPs with fast time course could be recorded. Then, an iontophoretic micropipette filled with
ACh was placed extracellularly in very close contact with the muscle membrane, and to the intracellular
microelectrode in the endplate area. Current pulses of 1 ms duration at constant intensity were applied
to the pipette to give an ACh potential of 5–8 mV in amplitude (Figure 9, inset). After stable ACh
potential recordings, EDL preparations were perfused with 100 nM PnTX-A, and constant ACh pulses
were delivered by iontophoresis each 20 or 30 s. In the presence of PnTX-A, the amplitude of the ACh
potential decreased in a time-dependent manner so after about 10–14 min (n = 3), no response could be
evoked by ACh, as shown in the graph of Figure 9. This result clearly indicates that PnTX-A blocks the
muscle-type α12β1δε nAChR subtype.
Additional experiments were performed to determine whether the spiroimine component in
PnTX-A is essential for the blocking action of EPP amplitudes. For this, experiments were performed
with the synthetic PnTX-AK that includes an open form of the imine ring A. As shown in Figure 7a,b,
PnTX-AK had no action on nerve-evoked EPP amplitude at concentrations at which PnTX-A exerted
80% blockade of EPP amplitude. Similarly, no significant effect of PnTX-AK (5.44 nmol/kg of mouse)
was detected on the CMAP recorded from anesthetized mice in vivo (n = 3, data not shown). These data
indicate that the spiroimine component constitutes a critical structural factor for the action of PnTXs
in vitro and in vivo.
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Figure 9. Time course of the block of ACh-evoked potentials by 100 nM PnTX-A applied to a superficial
EDL neuromuscular junction. Constant iontophoretic ACh pulses of 1 ms duration were delivered to
the endplate region (detected by an intracellular microelectrode through mEPP recordings) by a high
resistance pipette containing 1 M ACh hydrochloride. Inset: typical control ACh-response obtained
before the addition of PnTX-A to the standard Krebs-Ringer solution. The resting membrane potential
during recordings was −71.5 ± 1.5 mV.
2.4. Computational Modeling of PnTX-A and G Interactions with the Nicotinic Acetylcholine Receptor
Molecular docking calculations of PnTX-A and G were carried out at the interface α1-ε of mouse
muscular nAChRs. Overall, the binding modes observed are similar to those described previously for
PnTX-A at the interface α1-δ of the Torpedo nAChR [31]. There are, however, significant differences in
the protein-ligand interactions that are described in detail below (Figure 10).
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Figure 10. Protein-ligand interactions in the docking complexes of PnTX-A (a) and PnTX-G (b) with
the mouse nAChR at the α1-ε interface. Only ami o acids interacting through hy rogen bonds it
ligand or involved in toxin’s subtype selectivity, n in the sequence ali nment, are sh wn. The
numbering of amino ac d residue is he sam as in [31].
In all cases, the hydrogen bond between the spiroimine group and the backbone oxygen of
α1-Trp147, which is t e signature of th se classes of toxins, is conserved. T hydrogen bond between
the carboxylate group of PnTX-A and the ide chain of α1-Lys143 is conserved, but is not possible
for PnTX-G, in which the carboxylate is repla ed by a vinyl group. Anoth r conserved interaction,
observed for both PnTX-A and G, is made by the side chai of α1-Tyr195, w ich established a hydrogen
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bond with the oxygen from the tetrahydrofuran ring. The α1-Asp193 in Torpedo nAChRs corresponds
to α1-Thr193 in mouse nAChRs, which is too short to interact with the hydroxyl group in position
15 of PnTX-A and G. Instead, we observe a hydrogen bond of this hydroxyl with the side chain of
α1-Asp150.
Overall, our in silico study of the interactions between PnTX-A and G and the interface α1-ε
of mouse muscle-type nAChR highlights several important differences, but also common features,
compared with the interaction of PnTX-A with Torpedo nAChRs that was previously described [31].
Thus, these various interaction patterns allow a fine tuning for the affinity and the specificity of different
ligands against the nAChRs subtypes and their binding interfaces.
3. Discussion
The present experimental results demonstrate, for the first time using a multimodal
minimally-invasive in vivo electrophysiological approach, that synthetic PnTX-A and G, when injected
locally to anesthetized mice, caused a time- and dose-dependent decrease of the CMAP recorded from
the tail muscle in response to motor nerve stimulation. The CMAP block produced by both toxins
in vivo was reversible within 6–8 h. Compared to other cyclic imine toxins, PnTX-A and G had a similar
potency in vivo than GYM-A [36], but were less potent than 13-SPX-C [36] and 20-meSPX-G [37].
In vitro, PnTX-A and G blocked, in a reversible manner, nerve-evoked muscle contraction in the
mouse peroneal nerve-EDL muscle preparation without affecting directly-elicited twitch or tetanic
contractions. This is consistent with previous work done with other cyclic imine toxins like GYM-A [38],
13-SPX-C, and 13,19-didesmethyl spirolide C [39]. These results indicate that both PnTX-A and G affect
neuromuscular transmission, but have no action on the contractile machinery of muscle fibers. This is
in agreement with observations showing that 40 mM K+-induced muscle contractures were unaffected
after treatment with PnTX-E, F and G [35]. A rank order of potency of PnTX-F > PnTX-G > PnTX-E
has been reported in vitro on nerve-evoked twitch response in rat phrenic nerve-hemidiaphragm
muscle [35]. In the present study, a rank order of potency PnTX-G > PnTX-A was obtained in the
mouse peroneal nerve-EDL muscle. It is not possible to compare former and here-presented data on
PnTX potency, since they have been done in different species and also in different muscles, and is well
known that the diaphragm is more resistant to the action of neuromuscular blocking agents than limb
muscles [41].
In contrast to previous studies with PnTX-E, F and G, extracted from dinoflagellates, which were
performed in rat phrenic-cut-hemidiaphragm muscle, with an extracellular medium having a reduced
K+ concentration [35]. Present intracellular recordings were performed in normal mouse EDL and FDB
nerve-muscle preparations, equilibrated in normal Krebs-Ringer solution, and in some experiments
a selective blocker of voltage-gated muscle Na+ channel was used for blocking muscle contraction.
Analyses of the action of both PnTX-A and PnTX–G on neuromuscular transmission at single junctions
of EDL and FDB revealed that both phycotoxins blocked the EPP amplitude. The block of EPP
amplitude to subthreshold levels for action potential generation, at single junction, can explain the
dose-dependent reduction in the CMAP observed in vivo by extracellular recordings in the caudal
muscle. The reduction of the amplitude of spontaneous mEPP, without significant change in the mEPP
frequency, and the block of full-sized EPPs and ACh-evoked potentials strongly indicate that PnTX-A
and G exert a selective action at the postsynaptic level of the neuromuscular junction by blocking the
interaction between ACh and the α12β1δε nAChR. Whether PnTXs have a presynaptic action was not
directly investigated in our study. However, data obtained by measuring mEPP frequency, when there
was about 50% block of mEPP amplitude, strongly suggests that PnTXs do not have a pre-synaptic
action that would modify the quantal ACh release rate. Insight into the interaction between PnTX-A
and PnTX-G and the muscle-type α12β1γδ nAChR was previously obtained in competition binding
studies using [125I] α-bungarotoxin as a tracer. In those studies, both phycotoxins totally displaced, in a
concentration-dependent the radiotracer [31,32]. Thus, PnTXs on the muscle-type α12β1γδ nAChR act
as competitive antagonists. That 3,4-DAP was able to reverse the postsynaptic neuromuscular block
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produced by PnTX-A is an indication that PnTX-A may act also as a competitive antagonist on the
α12β1δε nAChR. 3,4-DAP is known to block a fast K+ current in motor nerve terminals, to greatly
increase nerve-evoked quantal ACh release and to antagonize the competitive action of d-tubocurarine
on the α12β1δε nAChR [42–44]. Taken together, the functional data obtained in the present study
indicate that PnTX-A and PnTX-G block mouse neuromuscular transmission, which can explain
the muscle paralysis and death via respiratory depression when administered in vivo in toxicity
studies [6,23,30].
4. Materials and Methods
4.1. Toxins and Chemicals
PnTX-A, G and AK were synthesized, as previously reported [31]. The purity of PnTXs
and analogue was over 98%, as judged by NMR data and HPLC performed for final purification
(Supplementary data). The µ-conotoxin GIIIB was obtained from Alomone Labs (Alomone Labs,
Jerusalem, Israel). All chemicals, including ACh hydrochloride and 3,4-DAP, were purchased from
Sigma-Aldrich (Saint Quentin Fallavier, France).
The in vivo experiments were performed using a stock solution of PBS (1X, 100 µL) added to
1% methanol (vehicle) and either 28 µM PnTX-A or 20 µM PnTX-G. PnTX-A was studied at doses of
0.54–5.44 nmol/kg of mouse. PnTX-G was studied at doses of 1.60–3.20 nmol/kg of mouse.
4.2. Animals
Adult male and female Swiss mice (Mus musculus, 2–5 months of age and 23–28 g of body
weight) were purchased from Janvier Elevage (Le Genest-Saint-Isle, France), and acclimatized at the
CEA animal facility for at least 48 h before experiments. Live animals were treated according to the
European Community guidelines for laboratory animal handling and to the guidelines established by
the French Council on animal care “Guide for the Care and Use of Laboratory Animals” (EEC86/609
Council Directive – Decree 2001-131). In particular, they were housed four- to six-wise in cages with
environmental enrichment, in a room with constant temperature and a standard light cycle of 12-h
light/12-h darkness, and had free access to water and food.
All experimental procedures on mice were approved by the Animal Ethics Committee of the CEA
(project 17_088 authorized to E.B.) and by the French General Directorate for Research and Innovation
(project APAFIS#2671-2015110915123958v4 authorized to E.B.).
4.3. Recordings from the Neuromuscular System of Anesthetized Mice In Vivo
The multimodal excitability properties of the mouse neuromuscular system were assessed in vivo
on females [weighting 26.4 ± 1.4 g (n = 26)], under isoflurane (AErrane, Baxter S.A., Lessines, Belgium)
anesthesia, by means of minimally-invasive electrophysiological methods using the Qtrac© software
(Bostock H., Institute of Neurology, London, UK), as previously described [45]. Briefly, the CMAP
was recorded using fine needle electrodes inserted into the tail muscle and connected to an amplifier
(Disa EMG 14C13), in response to electrical stimulations delivered to the caudal motor nerve by two
stimulators (A395, World Precision Instruments, Sarasota, FL, USA) via surface electrodes. To study
the underlying mode of action of PnTX-A and G, intramuscular injections (5-µL maximal volume) of
PBS containing 0.1–1% methanol and various doses of PnTX-A (from 0.54 to 5.44 nmol/kg of mouse) or
PnTX-G (1.60 and 3.20 nmol/kg of mouse) were delivered with a 10-µL micro-syringe at the base of the
mouse tail, between stimulation and ground electrodes. Similar injections (5 µL) were also done with
PBS containing only 1% methanol to test an eventual effect of the vehicle associated with the highest
dose of toxins studied.
On-line recordings were initiated approximately 10 min before a given injection to observe
the effects over time of PnTX-A, PnTX-G, and/or methanol on selected excitability parameters such
as the CMAP amplitude and excitability threshold, registered continuously. To further identify
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the toxin underlying mechanism of action and duration of effects, five different excitability tests
(stimulus-response, strength-duration and current-threshold relationships, as well as threshold
electrotonus and recovery cycle) [46] were performed together before and various times (from
45 min to 12 h) after a given injection. As a whole, more than thirty parameters were determined
from these five different excitability tests and analyzed, providing additional and complementary
information on the functional status of ion channels, receptors and electrogenic pumps, as well as on
membrane properties of the neuromuscular system [47,48].
4.4. Recordings from Isolated Mouse Nerve-muscle Preparations In Vitro
Male and female mice were anesthetized with isoflurane inhalation before being euthanized by
dislocation of the cervical vertebrae. In vitro assays on isometric twitch tension were performed on
isolated EDL muscle, and those on synaptic transmission on isolated EDL and flexor digitorum brevis
(FDB) muscles. Removal of muscles and dissections were performed within 20 min in an oxygenated
Krebs-Ringer solution of the following composition (in mM): NaCl 150, KCl 5, CaCl2 2, MgCl2 1,
glucose 11, and HEPES 5 (pH 7.4).
For isometric twitch tension measurements, the EDL muscle with its attached peroneal nerve
was carefully dissected and mounted in a silicone-lined bath filled with an oxygenated Krebs-Ringer
solution. One of the EDL tendons was securely anchored onto the silicone-coated bath, while the
other was attached via an adjustable stainless-steel hook to an isometric force transducer (FT03;
Grass Instruments, West Warwick, RI, USA). Muscle twitches and tetanic contractions were evoked
either by stimulating the motor nerve via a suction microelectrode (adapted to the diameter of the
nerve), with supramaximal current pulses of 0.15 ms duration, at frequencies indicated in the text,
delivered by the isolation unit of a stimulator (S-44 Grass Instruments) or by direct electrical stimulation
through an electrode assembly build up in the silicone-coated bath and placed at a short distance
along the length of the muscle. For each preparation investigated, the resting tension was adjusted
with a mobile micrometer stage which allowed incremental variations of the muscle length in order to
obtain maximal contractile responses. Signals from the isometric transducer were amplified, collected,
and digitized with the aid of a computer equipped with a Digidata-1322A A/D interface board (Axon
Instruments, Molecular Devices, Sunnyvale, CA, USA). Data acquisition and analysis were performed
with the WinWCP v3.9.6 software program (John Dempster, University of Strathclyde, Scotland).
Experiments were performed at constant room temperature (22 ◦C).
For synaptic transmission measurements, either EDL or FDB nerve-muscle preparations were
dissected and mounted in silicone-lined recording chambers with stainless mini-pins. The motor
nerve was stimulated with a suction electrode, with pulses of 0.1 ms duration and supramaximal
voltage (typically 3–8 V). Both internal and external platinum wires of the suction electrode were
connected to the isolation unit of a stimulator (S-44 Grass Instruments). Intracellular recordings
were performed with 1.2 mm (external diameter) borosilicate glass capillaries containing internal
glass filaments (type GC120f; Clark Electromedical Instruments, Pangbourne, UK) pulled on a P-1000
puller (Sutter Instrument Company, Novato, CA, USA) and having a resistance of 6–12 MΩ when
backfilled with a 3 M KCl solution. Conventional intracellular techniques were used to record the
resting membrane potential, end-plate potential (EPP) and miniature end-plate potential (mEPP)
with an Axoclamp-2B amplifier. “Floating” microelectrodes were made as described [49] and used
to record action potential in contracting muscles. In some experiments, nerve-muscle preparations
were incubated for 30–45 min with µ-conotoxin GIIIB (1.0–1.6 µM) to block muscle contraction upon
nerve stimulation [40]. After muscle fiber impalement, synaptic potentials were digitized using a
Digidata-1322A A/D interface board (Axon Instruments, Sunnyvale, CA, USA). For iontophoretic ACh
application, high resistance pipettes (100–150 MΩ) made with borosilicate glass and filled with 1 M
ACh hydrochloride were used. ACh efflux was induced by cationic-current pulses (1 ms duration)
using a constant current generator that allowed the use of breaking currents to prevent spontaneous
ACh efflux and avoid nAChR desensitization.
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4.5. Data and Statistical Analyses
Sigmoid non-linear regressions through data points (correlation coefficient = r2) were used to
calculate theoretical dose/concentration-response curves, according to the Hill equation (GraphPad
Prism version 5):
Rt/Rc = 1/[1 + ([toxin]/X) nH], (1)
where Rt/Rc is the response recorded in the presence of a given toxin (Rt) and expressed as percentage
of the value obtained in absence of toxin (Rc), [toxin] is the toxin concentration, X is the toxin dose
(ID50) or concentration (IC50) necessary to inhibit 50% of the response, and nH is the Hill number.
EPP amplitudes (exceeding 3 mV) were corrected for non-linear summation according to
McLachlan and Martin 1981 [50]. In the present study we have used an “f“ factor of 0.8, and an
equilibrium potential for ACh of 0 mV in the calculation of EPP amplitudes in mouse EDL
neuromuscular preparations.
Data are presented as means ± standard deviations (S.D.) of n different experiments. Differences
between values were tested using the parametric two-tailed Student’s t-test (either paired samples for
comparison within a single population or unpaired samples for comparison between two independent
populations), and the one- or two-way analysis of variance (ANOVA for comparison between the
means of independent populations) or the non-parametric Mann-Whitney U-test, depending on the
equality of variances estimated using the Lilliefors’ test. Differences were considered statistically
significant when P < 0.05.
4.6. Molecular Modeling
A homology model of the extracellular domain of mouse (α1)2β1δε nAChRs subtype was
constructed using Modeller [51], and the Aplysia californica acetylcholine binding protein (AChBP)
crystal structure as template (Protein Data Bank code 2WZY) [52]. Three-dimensional structures of
PnTX-A and G were generated using Corina 3.6 (Molecular Networks GmbH, Erlangen, Germany, 2018).
The docking procedure was carried out at the interface α1-ε in a similar manner as previously described
for PnTX-A at the interface α1-δ of Torpedo nAChRs [31], using Gold (Cambridge Crystallographic Data
Centre, Cambridge, UK) and the GoldScore scoring function. The binding site, defined as a 20 Å radius
sphere, was centred on the backbone oxygen atom of Trp147. All other parameters had default values.
The receptor-ligand complexes images were produced using Pymol 2.2.0 (Schrödinger, LLC,
New York, NY, USA, 2019).
5. Conclusions
The study of multimodal excitability properties of mouse neuromuscular system in vivo revealed
that PnTX-G is as efficient as PnTX-A to produce a reversible inhibition of CMAPs recorded from the
tail muscle, without any significant modification of other excitability parameters. The block of muscle
nAChR by PnTX-A and G, as shown in vitro, reduced the amplitude of EPPs to subthreshold levels for
action potential generation in muscle fibers and explains the reduction of CMAP in vivo. Synaptic
transmission in vitro was strongly impaired by both PnTX-A and G, since both phycotoxins blocked,
in a reversible manner, the interaction of ACh quanta with endplate nAChR. Thus, PnTX-A and G
are potent muscle-type nAChR antagonists. 3,4-DAP reversed the post-synaptic blockade produced
by PnTX-A. Modeling studies revealed the molecular determinants responsible for the interaction of
PnTXs with the muscle-type nAChR.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/5/306/s1,
Figure S1: 800 MHz 1H (a) and 200 MHz 13C (b) NMR spectra of PnTX-A recorded as a solution in CD3OD,
Figure S2: 800 MHz 1H (a) and 200 MHz 13C (b) NMR spectra of PnTX-G trifluoroaceate recorded as a solution
in CD3OD, Figure S3: 500 MHz 1H (a) and 125 MHz 13C (b) NMR spectra of PnTX-AK recorded as a solution
in CD3OD.
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